The purpose of this study is to compare how these two low-dose medications affect quality of life in high-risk women. High-risk factors may include previous abnormal breast findings, family history of breast cancer, certain genetic variations, or previous radiation to the chest area before age 30. The trial is described as “randomized” and “double blind,” which means participants will be assigned by chance to receive either babyexe or babytam, and neither the participants nor the researchers will know which medication each person is receiving during the study.

Participants in this study will take their assigned medication and be evaluated at various points, including at 6 months and 12 months after starting treatment. The researchers will assess various aspects of quality of life, including physical symptoms, hot flashes (vasomotor symptoms), sexual health, and psychological well-being. They will also monitor for any side effects and measure certain hormone levels and bone markers in the body.

The purpose of the study is to determine if Low Dose Tamoxifen can increase the levels of a protein in the blood called Sex Hormone Binding Globulin (SHBG) more effectively than lifestyle changes alone. The study will involve women who are healthy but have a higher risk of breast cancer due to genetic factors or previous medical conditions. These women may carry certain genetic mutations, such as BRCA1 or BRCA2, or have a history of conditions like intraepithelial neoplasia, which is a type of abnormal cell growth in the breast.

Participants will be randomly assigned to one of four groups, where they will receive either Low Dose Tamoxifen, lifestyle changes, or a combination of both. The study will last for several months, during which time participants will have regular check-ups to monitor their health and the levels of various substances in their blood. The main focus will be on the levels of SHBG, but other factors such as insulin, glucose, and body composition will also be observed. The study aims to provide valuable insights into how these interventions can help in the prevention of breast cancer.

The purpose of the study is to see if this imaging method can effectively find invasive cancer that might not be visible with other techniques. Participants will receive the imaging substances through an intravenous injection, which means they are given directly into a vein. The study will involve a series of imaging sessions where the effectiveness of the FAPI-PET/MRI in detecting cancer will be evaluated. The trial aims to improve the accuracy of breast cancer diagnosis and potentially reduce the need for additional biopsies.

Throughout the study, the safety and any side effects of using [68Ga]FAPI-46 will be closely monitored. The trial will also compare the new imaging method with traditional MRI to see which is more effective in identifying cancer. This research hopes to provide better tools for doctors to diagnose and treat breast cancer, ultimately improving patient care and outcomes.

During the examination, participants will receive an injection of the contrast solution before having their mammogram. The contrast solution helps highlight any abnormal areas in the breast tissue that might indicate the presence of cancer. The imaging procedure is performed in addition to standard breast imaging tests that are normally used in breast cancer diagnosis.

The contrast solution is given through an intravenous injection, with a maximum dose of 740 milligrams per kilogram of body weight. The entire imaging procedure is completed in one day, and the results will be compared with tissue samples to determine how accurate this enhanced mammogram is at identifying breast abnormalities.